Foundayo (orforglipron) is not registered in Singapore, and GetLean does not prescribe or supply it (HSA register; HSA approvals). For weight management, GetLean offers assessment for HSA-registered medicines at a S$20, 30-minute video consultation with Dr Quek. Where medication is prescribed, the programme includes delivery, monthly reviews and daily WhatsApp coaching; a consultation does not guarantee a prescription.
Retatrutide and orforglipron are not registered in Singapore, and GetLean does not prescribe or supply them. GetLean does prescribe and supply HSA-registered GLP-1 medications, after a consultation with Dr Quek.
Foundayo is the brand name of orforglipron, a once-daily GLP-1 tablet from Eli Lilly (MHRA). It was approved in the United States on 1 April 2026 (Drugs@FDA) and authorised in the United Kingdom on 10 August 2026, for weight management and for type 2 diabetes (MHRA). On 24 October 2026 it was not in the register's data, which runs to approvals of 8 July 2026, or among the approvals HSA lists to September 2026 (HSA register; HSA approvals).
Availability in Singapore. This medicine is not available in Singapore. It is not registered with the Health Sciences Authority, and GetLean does not prescribe or supply it. The grey-market guide covers products offered outside the registered prescription route.
Education only. This page is general education about a medicine that is not registered in Singapore. It is not an advertisement or an offer. GetLean does not prescribe or supply orforglipron (Foundayo), and nothing here recommends using it.
Small-molecule medicine: a medicine built from a small chemical structure rather than a chain of amino acids (a peptide). Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist (Wharton 2025).
Where it is approved
United States. Approved on 1 April 2026, with a further supplement approved on 4 August 2026 (Drugs@FDA). The US label indicates it, with a reduced-calorie diet and more physical activity, to reduce excess weight and keep it off in adults with obesity, or overweight with at least one weight-related condition (DailyMed).
United Kingdom. Authorised on 10 August 2026, the first approval in Europe, for weight loss and weight maintenance in adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition, and for type 2 diabetes. The MHRA notes it is not yet available on the NHS (MHRA).
Singapore. Not registered, as above. An approval elsewhere does not register a medicine here; that is a separate decision by the Health Sciences Authority.
What does overseas approval mean for availability here?
An overseas approval does not register Foundayo in Singapore; Singapore registration is a separate HSA decision.
| Jurisdiction | Dated evidence already checked for this page | Registration or availability distinction |
|---|---|---|
| United States | Original FDA approval 1 April 2026; supplement 4 August 2026 | Weight-management indication in the US label; not a Singapore registration |
| United Kingdom | MHRA authorisation 10 August 2026 | Weight management and type 2 diabetes; the announcement says not yet available on the NHS |
| Singapore | Register and approval listings checked 24 October 2026 | No Foundayo or orforglipron product found; GetLean does not supply it |
Sources: Drugs@FDA, US label, MHRA, HSA register and HSA approvals.
How it is taken
The UK authorisation describes a tablet taken once a day, at any time of day, with no food or water restrictions. Treatment starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, spending at least a month at each dose (MHRA). The most common side effects the MHRA lists are nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.
What the trials found, and how many people stopped
ATTAIN-1, a phase 3 trial, randomised 3,127 adults with obesity and without diabetes to once-daily orforglipron at 6 mg, 12 mg or 36 mg, or placebo, for 72 weeks (Wharton 2025). ATTAIN-2 randomised 1,613 adults with obesity or overweight and type 2 diabetes to the same three doses or placebo, also for 72 weeks (Horn 2025). Both were funded by Eli Lilly.
| Dose | ATTAIN-1 (no diabetes) | ATTAIN-2 (type 2 diabetes) |
|---|---|---|
| 6 mg | −7.5% | −5.1% |
| 12 mg | −8.4% | −7.0% |
| 36 mg | −11.2% | −9.6% |
| Placebo | −2.1% | −2.5% |
Average weight change at 72 weeks. Treatment-regimen estimand, counting everyone randomised (Wharton 2025; Horn 2025). Individual results vary and are not guaranteed.
On the 36 mg dose, 54.6% of participants lost at least 10% of their body weight, against 12.9% on placebo. Between 5.3% and 10.3% of those on orforglipron stopped because of side effects, against 2.7% on placebo, and the most common side effects were digestive and mostly mild to moderate (Wharton 2025). In ATTAIN-2, 6.1% to 9.9% on orforglipron stopped because of side effects, mainly digestive, against 4.1% on placebo (Horn 2025).
Stopping, in the US label. Across the two weight-management trials pooled in the US label, 8% of people on orforglipron (6%, 9% and 10% across the three doses) permanently stopped treatment because of side effects, against 3% on placebo; most of them, 5%, stopped because of stomach and gut reactions (US label). Foundayo side effects sets out the label's side effects in full.
Against the tablet registered here. ACHIEVE-3 compared orforglipron with oral semaglutide, open-label, in 1,698 adults with type 2 diabetes for 52 weeks; its main result was HbA1c, a blood-sugar measure, not weight (Rosenstock 2026). HbA1c fell by 1.71% and 1.91% on the two orforglipron doses and by 1.23% and 1.47% on the two oral semaglutide doses, and orforglipron was reported as non-inferior and superior on that measure. Stomach and gut events (59% and 58% against 37% and 45%) and stopping because of side effects (9% and 10% against 4% and 5%) were higher on orforglipron; individual results vary.
After an injection. In ATTAIN-MAINTAIN, adults who had lost weight on tirzepatide (205) or semaglutide (171) were randomised to orforglipron or placebo; among those at a weight plateau, orforglipron kept a model-based 74.7% and 79.3% of the weight reduction at week 52, against 49.2% and 37.6% on placebo (Aronne 2026). It had no arm continuing the injection and lasted one year, and individual results vary.
The overview of what is coming sets these figures beside the trial results of other medicines in development, and Reta vs Mounjaro, Foundayo vs the Wegovy pill sets the orforglipron trials beside those of the Wegovy pill and Mounjaro, as the separate trials they are. Foundayo vs Wegovy pill: which works better? goes through the two tablets' trials, the indirect comparison and the side effects in more detail.
Does Foundayo have a boxed warning?
Yes, in the United States. These are the US label's words; Foundayo has no Singapore label. The boxed warning is headed "WARNING: RISK OF THYROID C-CELL TUMORS" and its first paragraph reads:
In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)]. (US label)
The label contraindicates Foundayo in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in people with a known serious hypersensitivity to orforglipron or any of its excipients. Its other warnings and precautions are headed: acute pancreatitis; severe gastrointestinal reactions; acute kidney injury due to volume depletion; hypoglycemia; hypersensitivity reactions; diabetic retinopathy complications in patients with type 2 diabetes; acute gallbladder disease; and pulmonary aspiration during general anesthesia or deep sedation (US label). The Foundayo side-effects page sets out the label's side-effect table.
How it differs from the tablet registered here
The only GLP-1 tablet on Singapore's register is oral semaglutide, sold as Rybelsus, at 3 mg, 7 mg and 14 mg (HSA register). Its registered indication here is type 2 diabetes, with no weight-management indication (Singapore NDF). The Rybelsus page explains what that means.
Orforglipron is a different medicine, not a new form of semaglutide. It is a small-molecule, non-peptide GLP-1 receptor agonist (Wharton 2025), and its UK authorisation includes weight management as well as type 2 diabetes (MHRA). If it is ever registered in Singapore, the indication it carries here will be whatever HSA approves, which need not match the US or UK label.
When could Foundayo be registered in Singapore?
No date can be given. It was approved in the United States on 1 April 2026 (Drugs@FDA) and authorised in the United Kingdom on 10 August 2026 (MHRA), but an approval elsewhere does not register a medicine here; that is a separate decision by the Health Sciences Authority.
HSA's abridged route covers a product approved by at least one drug regulatory agency, and its verification route one approved by at least two of its reference agencies, a list that includes the FDA and the MHRA (HSA routes). HSA's published target times for a new drug application are 50 working days for screening, then 60 for evaluation on the verification route, 180 on the abridged route and 270 on the full route, not counting the applicant's time to answer HSA's questions (HSA fees).
Those times begin when a company applies, and none of the sources used for this page says whether an application has been made in Singapore, so nothing here should be read as a sign that a date is near. On 24 October 2026, no product named Foundayo, and none containing orforglipron, was on Singapore's register or among the approvals HSA lists to September 2026 (HSA register; HSA approvals). If it is ever registered here, the indication it carries will be whatever HSA approves, which need not match the US or UK label. Retatrutide and orforglipron are not registered in Singapore, and GetLean does not prescribe or supply them. GetLean does prescribe and supply HSA-registered GLP-1 medications, after a consultation with Dr Quek.
What can GetLean assess while Foundayo is unavailable here?
GetLean assesses whether an HSA-registered GLP-1 medicine suits you; it does not prescribe or supply Foundayo. Oral semaglutide, Rybelsus, is registered here for type 2 diabetes only, so prescribing it for weight is off-label (Singapore NDF). Dr Quek decides suitability at your consultation.
- Book your consult. Tell us your health history, goals and any medicines you already take.
- Meet Dr Quek by video for 30 minutes. The first consultation is S$20. A consultation does not guarantee a prescription.
- If he prescribes a medicine GetLean supplies, it is delivered to you, with daily WhatsApp coaching and Dr Quek's monthly reviews.
The pricing page lists the actual programme prices; there is no GetLean Foundayo price. The GLP-1 programme includes a personalised nutrition and daily activity plan and the planned taper. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. Individual results vary. This describes medicines GetLean prescribes, not Foundayo.
Coming off a GLP-1 tablet concerns the semaglutide tablet, not a Foundayo taper protocol. Foundayo side effects remains education about the overseas label. If treatment causes symptoms at GetLean, anything clinical goes to Dr Quek through the care team on WhatsApp; urgent symptoms do not wait for a reply or the next review.
Read the transcript
What is Foundayo? Orforglipron: what is it, and how does it work?
Foundayo is the brand name of orforglipron, a once-daily GLP-1 tablet from Eli Lilly. It's approved in the US and the UK.
I'm Dr Quek, a Singapore-registered doctor, and the doctor behind the GetLean GLP-1 Taper Plan.
Retatrutide and orforglipron are not registered in Singapore, and GetLean does not prescribe or supply them.
How does it work, and how is it taken?
Orforglipron is a GLP-1 receptor agonist, and a small-molecule one. That means a medicine built from a small chemical structure, rather than a chain of amino acids.
In the UK, it's a tablet taken once a day, at any time of day, with no food or water restrictions.
How much weight did people lose?
In a seventy-two-week trial of more than three thousand adults with obesity, without diabetes, weight fell by about eleven percent on average on the highest dose. On placebo, about two percent.
Eli Lilly funded the trial.
What are the side effects?
The most common side effects the UK regulator lists are nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.
In the US label's pooled trials, eight in a hundred on Foundayo permanently stopped because of side effects, against three on placebo.
Does Foundayo have a boxed warning?
Yes, in the US: the label's boxed warning is headed risk of thyroid C-cell tumours.
In rodents, thyroid tumours were seen with products in this class that are active in rats and mice, but orforglipron isn't active in rats or mice, and didn't produce tumours in rodents.
But it is active at the human GLP-1 receptor, and the human relevance of those rodent tumours has not been determined.
When could Foundayo be registered in Singapore?
No date can be given, as none of the sources I've used says whether an application has been made here.
No doctor in Singapore can prescribe it, and there is no legitimate local supply.
Anything offered under the Foundayo name in Singapore is coming from outside the regulated system.
If you're considering GLP-1 medication to reach your weight goal, and you'd like to taper off it one day, I invite you to visit getleanclinic.sg to learn about our approach and the GetLean GLP-1 Taper Plan.
Common questions
Is Foundayo available in Singapore?
No. No product named Foundayo, and none containing orforglipron, is on Singapore's register of therapeutic products (HSA register) or among the new drugs HSA approved from January to August 2026 (HSA approvals), checked 8 October 2026. It is approved in the United States (Drugs@FDA) and the United Kingdom (MHRA).
Is Foundayo the same as orforglipron?
Yes. Foundayo is the brand name of orforglipron, as the UK regulator's announcement records (MHRA).
How is Foundayo taken?
In the UK it is taken once a day, at any time of day, with no food or water restrictions. Treatment starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with at least a month at each dose (MHRA).
How much weight did people lose on orforglipron?
In the phase 3 trial ATTAIN-1, average weight change at 72 weeks was −7.5%, −8.4% and −11.2% on 6 mg, 12 mg and 36 mg, against −2.1% on placebo (Wharton 2025). Individual results vary and are not guaranteed.
How is it different from Rybelsus?
Rybelsus is a semaglutide tablet, registered in Singapore at 3 mg, 7 mg and 14 mg for type 2 diabetes only (HSA register; Singapore NDF). Orforglipron is a different medicine, a small-molecule, non-peptide GLP-1 tablet (Wharton 2025), and it is not registered here.
Does Foundayo have a boxed warning?
Yes. The US label carries a boxed warning headed “WARNING: RISK OF THYROID C-CELL TUMORS”, which says that “the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined” (US label).
When will Foundayo be available in Singapore?
No date can be given. It is not registered in Singapore, and none of the sources used for this page says whether an application has been made here (HSA register; HSA approvals). HSA's published target times for a new drug application start only when a company applies (HSA fees).
What are the uses of orforglipron tablets?
In the United States, orforglipron is approved, with a reduced-calorie diet and more physical activity, to reduce excess weight and keep it off in adults with obesity, or overweight with at least one weight-related condition (DailyMed); in the United Kingdom it is also authorised for type 2 diabetes (MHRA). It has no approved use in Singapore, where it is not registered (HSA register).
How much does Foundayo cost in Singapore?
There is no GetLean Foundayo price: it is not registered here and GetLean does not prescribe or supply it (HSA register; HSA approvals). The pricing page lists medicines and programmes GetLean actually supplies. A S$20, 30-minute video consultation with Dr Quek assesses whether a registered treatment suits you; it is not a Foundayo prescription offer.
Which GLP-1 tablet does GetLean supply instead?
GetLean supplies Rybelsus, oral semaglutide, after Dr Quek's assessment. Singapore registers its 3 mg, 7 mg and 14 mg tablets for type 2 diabetes only, so prescribing it for weight is off-label (HSA register; NDF). Rybelsus is a different medicine from Foundayo, not a locally branded version of it.
Is Foundayo the same as the Wegovy pill?
No. Foundayo contains orforglipron, a small-molecule GLP-1 medicine; the Wegovy pill contains semaglutide (Wharton 2025; Foundayo vs Wegovy pill). Neither tablet is registered in Singapore. The comparison page sets their separate trials side by side without presenting them as a head-to-head trial.
Is orforglipron a peptide?
No. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist (Wharton 2025). It is a different molecule from semaglutide, not a new semaglutide formulation, and overseas approval does not make it a registered Singapore treatment.
What are the common side effects of Foundayo?
The UK regulator lists nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain (MHRA). These are facts about an overseas authorisation, not a Singapore label. Foundayo side effects covers the US label and trial data in detail.
Who should not take Foundayo under the US label?
The US label contraindicates Foundayo in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in those with known serious hypersensitivity to orforglipron or its ingredients (US label). Foundayo has no Singapore label, and GetLean does not prescribe or supply it.
How many people stopped orforglipron because of side effects?
In ATTAIN-1, 5.3% to 10.3% on orforglipron stopped because of adverse events, against 2.7% on placebo (Wharton 2025). The most common effects were digestive and mostly mild to moderate. These are trial averages, and individual results vary; the side-effects page explains the trial and US-label figures separately.
Has orforglipron been compared directly with Rybelsus?
ACHIEVE-3 compared orforglipron with oral semaglutide in an open-label trial of 1,698 adults with type 2 diabetes for 52 weeks (Rosenstock 2026). Its main outcome was HbA1c, a blood-sugar measure, not weight; stomach and gut events and stopping because of side effects were higher on orforglipron. That is not a head-to-head weight-loss result for adults without diabetes.
Can Foundayo replace an injection after weight loss?
ATTAIN-MAINTAIN studied orforglipron after tirzepatide or semaglutide, but had no arm continuing the injection and lasted one year (Aronne 2026). It does not establish a Singapore switching protocol: Foundayo is not registered here, and GetLean does not supply it. For medicines GetLean prescribes, the GetLean GLP-1 Taper Plan is set at Dr Quek's monthly reviews towards the lowest effective dose and, where clinically appropriate, off the medication.